Cargando…
Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior to IFX infusions has been used in clinical practice, but its eff...
Autores principales: | Szymanska, Edyta, Dadalski, Maciej, Sieczkowska-Golub, Joanna, Jarzebicka, Dorota, Meglicka, Monika, Osiecki, Marcin, Wiernicka, Anna, Lebensztejn, Dariusz M., Korczowski, Bartosz, Kierkus, Jaroslaw |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303466/ https://www.ncbi.nlm.nih.gov/pubmed/34300342 http://dx.doi.org/10.3390/jcm10143177 |
Ejemplares similares
-
Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015) -
Effect of the Crohn’s Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn’s Disease
por: Matuszczyk, Małgorzata, et al.
Publicado: (2022) -
Usefulness of Colon Assessment by Magnetic Resonance Enterography in Pediatric Patients with Inflammatory Bowel Disease—Retrospective Case Series
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2021) -
The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis
por: Szymańska, Edyta, et al.
Publicado: (2020) -
Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study
por: Wlazło, Magdalena, et al.
Publicado: (2022)